NorthStar Medical Radioisotopes announced today the first patient to be treated using the radioisotope Copper-67 (Cu-67) produced from its electron accelerator. 

According to a release, the administration of the therapeutic dose took place during a clinical trial led by Clarity Pharmaceuticals.

“The fact that the initial human use of NorthStar’s electron accelerator-produced Cu-67 is in a clinical trial designed to treat children with high-risk neuroblastoma underscores the importance of our work in advancing innovation to promote patient health, and we hope that we can help children and their caregivers who are affected by this serious disease,” NorthStar Medical Radioisotopes’ President and CEO Frank Scholz said in a statement.

The clinical trial is being conducted across eight clinical sites in the United States with up to 34 patients.